A recent study[57] demonstrated that baricitinib, a JAK1 and JAK2 inhibitor, suppressed the destruction of acinar cells in the salivary gland of pSS patients by abrogating IFN-γ-induced CXCL10 expression and CXCL10-dependent immune cell infiltration in human salivary gland ductal cells. Here, JAK1 is linked to peeling skin syndrome.